As part of the trial, a series of 24-hour baseline testing was completed in multiple ways with two different versions of the device commonly used throughout the NHS and healthcare facilities – the 3rd edition T34™ and the next generation BD BodyGuard™ T.
Steve Webb from GMS comments, “Best practice advice is for trusts to complete a risk assessment before deploying RFID devices. This pilot trial, part of a subset of tests to be carried out, has instilled confidence that GMS have successfully demonstrated the asset tracking tag does not interfere with the BodyGuard™ T during a normal infusion. The flow rate and delivery of medicines are consistent with that of a device without a tag.”
Steve continued, “As with many trusts, the portability of BodyGuard™ T syringe drivers means that many can be misplaced around the hospital or lost within the community. As such, we needed a robust and streamlined solution to accurately track these mobile devices wherever they are used. This pilot has successfully proved the value of medical device tracking and is an important first step in mitigating any concern around EMI and using tracking tags on sensitive equipment.”
For more information on Idox’s BodyGuard™ T lockbox and medical device tracking solutions, contact firstname.lastname@example.org.